Cargando…
The therapeutic prospects of N-acetylgalactosamine-siRNA conjugates
RNA interference has become increasingly used for genetic therapy following the rapid development of oligonucleotide drugs. Significant progress has been made in its delivery system and implementation in the treatment of target organs. After a brief introduction of RNA interference technology and si...
Autores principales: | Zhang, Lei, Liang, Yayu, Liang, Guohui, Tian, Zhili, Zhang, Yue, Liu, Zhihui, Ji, Xinying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794871/ https://www.ncbi.nlm.nih.gov/pubmed/36588695 http://dx.doi.org/10.3389/fphar.2022.1090237 |
Ejemplares similares
-
Plasma Pharmacokinetics of N-Acetylgalactosamine-Conjugated Small-Interfering Ribonucleic Acids (GalNAc-Conjugated siRNAs)
por: Sten, Sebastian, et al.
Publicado: (2023) -
Liver-Targeted Delivery of Oligonucleotides with N-Acetylgalactosamine Conjugation
por: Cui, Hao, et al.
Publicado: (2021) -
Insight Into the Prospects for RNAi Therapy of Cancer
por: Tian, Zhili, et al.
Publicado: (2021) -
Development of Triantennary N-Acetylgalactosamine
Conjugates as Degraders for Extracellular Proteins
por: Zhou, Yaxian, et al.
Publicado: (2021) -
Inclisiran: a new generation of lipid-lowering siRNA therapeutic
por: Zhang, Yanzhen, et al.
Publicado: (2023)